Brightgene Bio-medical Technology Co (SHSE:688166) Institutional Ownership: 8.69% (As of Aug. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688166 Brightgene Bio-medical Technology Co Ltd SHSE:688166
83 GF Score
Price ¥40.34
GF Value ¥38.69
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Brightgene Bio-medical Technology Co Institutional Ownership?

Brightgene Bio-medical Technology Co SHSE:688166 -3.65% 83 Institutional Ownership is 8.69% as of Aug. 14, 2026. GuruFocus rates SHSE:688166 with a GF Score™ of 83/100 and a GF Value™ of ¥38.69 (Fairly Valued). The stock has 7 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Brightgene Bio-medical Technology Co's institutional ownership is 8.69%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Brightgene Bio-medical Technology Co's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Brightgene Bio-medical Technology Co's Float Percentage Of Total Shares Outstanding is 0.00%.

Brightgene Bio-medical Technology Co Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Brightgene Bio-medical Technology Co's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Brightgene Bio-medical Technology Co Institutional Ownership Chart

Brightgene Bio-medical Technology Co Historical Data

The historical data trend for Brightgene Bio-medical Technology Co can be seen below:

2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31
Institutional Ownership 7.03 7.02 8.95 8.95 8.95 8.95 8.95 8.69 8.69 8.69
SHSE:688166
83GF Score
Brightgene Bio-medical Technology Co Ltd SHSE:688166
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Brightgene Bio-medical Technology Co Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 8.69% mean?
Brightgene Bio-medical Technology Co (SHSE:688166) has a Institutional Ownership of 8.69% as of Aug. 14, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Brightgene Bio-medical Technology Co and its competitors.
Is Brightgene Bio-medical Technology Co's Institutional Ownership too high?
Brightgene Bio-medical Technology Co's current Institutional Ownership is 8.69%. Overall, Brightgene Bio-medical Technology Co has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Brightgene Bio-medical Technology Co's Institutional Ownership compare to VRTX and REGN?
Brightgene Bio-medical Technology Co's Institutional Ownership of 8.69% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Brightgene Bio-medical Technology Co and its competitors. Brightgene Bio-medical Technology Co's current Institutional Ownership is 8.69%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brightgene Bio-medical Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Brightgene Bio-medical Technology Co (SHSE:688166) is currently considered Fairly Valued. The stock's GF Value™ is ¥38.69, compared to a current price of ¥40.34 — trading 4.3% above its estimated fair value. The current Institutional Ownership is 8.69%. Brightgene Bio-medical Technology Co's overall GF Score™ is 83/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Brightgene Bio-medical Technology Co (SHSE:688166), the current Institutional Ownership is 8.69% as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Brightgene Bio-medical Technology Co (SHSE:688166) Overvalued in 2026?

Based on GuruFocus' analysis, Brightgene Bio-medical Technology Co stock appears to be overvalued. The current stock price of ¥40.34 is trading 4.3% above its estimated GF Value™ of ¥38.69. GuruFocus considers Brightgene Bio-medical Technology Co to be Fairly Valued.

Key valuation signals for SHSE:688166:

  • Institutional Ownership: 8.69%
  • GF Value™: ¥38.69 vs. price of ¥40.34 (4.3% above fair value)
  • GF Score™: 83/100 with 7 warning signs

No single metric tells the full story. See the SHSE:688166 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Brightgene Bio-medical Technology Co Business Description

Address No. 218 Xinghu Street, Buildings C25-C28, Nanotechnology Park, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215123
Brightgene Bio-medical Technology Co Ltd is engaged in the Research and development and production of pharmaceutical intermediates, active pharmaceutical ingredients and formulations with high technological barriers.
83GF Score

Get the complete analysis for SHSE:688166

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥40.34
Price
¥38.69
GF Value